Gantenerumab in Early Alzheimer's Disease.

The article focuses on the efficacy of gantenerumab in early Alzheimer's disease, highlighting its impact on amyloid levels but not on tau levels as observed in the GRADUATE trials. Topics include the potential implications of limited amyloid plaque clearance, the lack of effect on tau levels by various anti-amyloid drugs, and the need for further exploration of the relationship between amyloid-beta and tau pathology in Alzheimer's disease progression.